The Similkameen Spotlight: Princeton ‘magic mushroom’ facility holds open house



Optimi Co-Founder & COO, Bryan Safarik


A new “magic mushroom” facility in Princeton is opening its doors to locals as the psilocybin industry starts to take shape all across British Columbia.

The grand opening event on Friday, May 27, is set to begin at about 10:45 a.m. and include a free barbecue and tour of the operation.

Optimi Health is Canada’s largest producer of natural, GMP-certified psilocybin and functional mushrooms, and is celebrating the start up of its 20,000-square-foot operation in the town’s industrial park.

Bryan Safarik of Vancouver is one of Optimi Health’s founders. He and other partners also started BC Green Pharmaceuticals, which operates two other plants in Princeton that produce medical-grade cannabis.

“Between research into already-existing compounds such as LSD and psilocybin (magic mushrooms) and the race to develop new drugs, important steps toward access for patients suffering from depression and end-of-life distress as a result of terminal diagnoses are already being taken here in Canada, many right in our own backyard here in British Columbia,” explained Safarik.

North American researchers are starting to focus on peer-reviewed studies to determin how mushrooms can treat anxiety, post-traumatic stress disorder and substance use disorders.

Safarik described the possibilities for psilocybin as “tantalizing” but cautioned more research needs to be done before its use is approved.

“Psilocybin shows potential, but to back up these early results with enough evidence to ensure that health regulators are willing to utilize this life changing, natural medicine, there will need to be more data.”

Noting the promise of new jobs for Princeton, Safarik said he hopes locals turns out of the open house.

“From these simple mushrooms can come big things. We’d be honoured if you would join us to be part of them, together, from day one,” said Safarik.

“The entire community of Princeton has played a role in getting Optimi to where it is today, and with that support it’s now our turn to say thank you. So please join us on May 27 as we open Optimi and Princeton to the world.”

Source: The Similkameen Spotlight




Investor Relations
Phone: +1 (902) 880 6121


Optimi Health Corp. is a Canadian-based company licensed by Health Canada to produce and supply natural, EU-GMP grade psilocybin and synthetic psychedelic substances, as well as functional mushrooms that focus on the health and wellness markets. Built with the purpose of producing scalable psychedelic formulations for transformational human experiences, the Company’s goal is to be the number one trusted, compassionate supplier of safe drug products throughout the world. Optimi’s products are grown at its two facilities comprising a total of 20,000 square feet in Princeton, British Columbia, making it the largest psilocybin and MDMA cultivator in North America.


Investor Relations
Phone: +1 (902) 880 6121


This news release contains forward‐looking statements and forward‐looking information within the meaning of Canadian securities legislation (collectively, “forward‐looking statements”) that relate to Optimi’s current expectations and views of future events. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, through the use of words or phrases such as “will likely result,” “are expected to,” “expects,” “will continue,” “is anticipated,” “anticipates,” “believes,” “estimated,” “intends,” “plans,” “forecast,” “projection,” “strategy,” “objective,” and “outlook”) are not historical facts and may be forward‐looking statements and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ materially from those expressed in such forward‐looking statements. No assurance can be given that these expectations will prove to be correct and such forward‐looking statements included in this news release should not be unduly relied upon. These statements speak only as of the date of this news release. In particular and without limitation, this news release contains forward‐ looking statements pertaining to activities proposed to be conducted under the Company’s dealer’s license and associated business related to Psilocybin and Psilocin and Optimi’s plans, focus and objectives.

Forward‐looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond Optimi’s control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward‐looking statements. Such risks and uncertainties include, but are not limited to, the impact and progression of the COVID‐19 pandemic and other factors set forth under “Forward‐Looking Statements” and “Risk Factors” in the Company’s Annual information Form dated January 12, 2022, and other continuous disclosure filings available under Optimi’s profile at Optimi undertakes no obligation to update or revise any forward‐looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. New factors emerge from time to time, and it is not possible for Optimi to predict all of them or assess the impact of each such factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward‐looking statement.

Any forward‐looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement.

Products do not contain psilocybin

Get news & updates directly to your inbox.
Thank you for your interest in our investor presentation.

Please sign up here and we will send the presentation to your inbox.
Interested In Optimi? Let's Talk.